Galecto hires new Chief Medical Officer
pharmafile | February 7, 2020 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AstraZeneca, Galecto
Galecto has announced Bertil Lindmark as their new Chief Medical Officer. He began his posting on 1 February 2020.
Lindmark joins from the eTheRNA immunotherapies, which is a Belgian mRNA immunotherapy company. He has also had an extensive and successful career in the pharmaceutical industry.
Hans Schambye, the Chief Executive Officer of Galecto, said: “We are very please to welcome Bertil to Galecto. His global background, deep scientific knowledge and leadership experience will further strengthen our ambitious targets as we progress GB0139 towards market and explore the potential of our exciting pipeline following the merger with PharmAkea.”
Lindmark was the Global Vice President of Clinical Development for the Respiratory and Inflammation franchises at AstraZeneca. It was here he led the development of Symbicort along with many other gastro-intestinal products. From 2010, he headed Research and Development at Almirall before joining ASLAN pharmaceuticals in Singapore where he focused on atopic skin and lung diseases as well as cancer.
In response to his appointment, Lindmark said: “I look forward to joining Galecto at such an important point in the company’s development. Galecto has a very promising combination of small molecule drug candidates in its pipeline: two targeting the role of galectin-3 in inhibiting cells involved in fibrosis, and one that inhibits LOXL2, a key enzyme involved in the formation of the extracellular matrix during the fibrotic process. These differentiated molecules in clinical phase form a strong foundation on which we aim to build a future global operation.”
Lindmark’s educational background is in medicine and gastroenterology and he obtained a PhD in molecular epidemiology from Lund University in Sweden. He was appointed a visiting professor at Gothenburg University for Innovation and Entrepreneurship at the Institute of Medicine.
Related Content
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …
Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …
